**Table VIIs - Clinical Trials**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **N°** | **PROTOCOL NUMBER** | **PRIMARY SPONSOR** | **COUNTRY** | **DATE OF 1st ENROLEMENT** | **STATUS** | **SAMPLE SIZE**  **(n° pts)** | **CLINICAL CONDITIONS** | **POPULATION AGE**  **(years)** | **INTERVENTION** | **COMPARATOR** | **OUTCOMES** | **RESULTS** |
| **1** | **NCT04084015 [25]** | Massachusetts General Hospital | not specified | 01.10.2019 | Not yet recruiting | 20 | CS | >=18 | Axillary Impella | no comparator | * 30-day after VA-ECMO cannulation or discharge: * survival * death from cardiovascular causes * left ventricular function * neurological functional status New York Heart Association functional status | not avaiable |

*Table:* *We report 1 registered clinical trials on the use of Impella 5.0. Unfortunately, the results of the involved trial are not included because it is on recruitment.*

*In our research we found other six Cinical Trials (Registration numbers: NCT04143893, NCT03378739, NCT02468778, NCT04184635, NCT04117230, NCT03528291, NTR3450) in which device group Impella is involved and that can provide further data on Impella 5.0.*

*Legend:*

VA ECMO (Venoarterial extracorporeal membrane oxygenation), CS (Cardiogenic Shock), pts (patients)